Lack of regional selectivity during the progression of Parkinson disease: Implications for pathogenesis

Archives of Neurology

Volumn 61, Issue 12, 2004, Pages 1920-1925

  Lee, Chong S ^a   Schulzer, Michael ^a   De La Fuente Fernandez, Raul ^a   Mak, Edwin ^a   Kuramoto, Lisa ^b   Sossi, Vesna ^b   Ruth, Thomas J ^c   Calne, Donald B ^a   Stoessl, A Jon ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c TRIUMF   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE RECEPTOR;

ADULT; AGED; ARTICLE; CALCULATION; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM SPECIFIC BINDING; MULTIVARIATE EXPONENTIAL MODEL; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; STATISTICAL MODEL;

AGED; BRAIN; DISEASE PROGRESSION; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; REGRESSION ANALYSIS; TETRABENAZINE;

EID: 10044247418     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.12.1920     Document Type: Article

References (38)

1. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med. 1988;318:876-880.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
3. Saper CB. "Like a thief in the night": the selectivity of degeneration in Parkinson's disease. Brain. 1999;122:1401-1402.
4. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:574-576.
5. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD; Royal Kings and Queens Parkinson's Disease Research Group. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol. 1992;32(suppl):S82-S87.
6. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol. 1998;44(suppl):S89-S98.
7. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol. 2003;53(suppl 3):S61-S70.
8. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003;179:38-46.
9. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A. 2003;100:5473-5478.
10. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 1995;38:357-366.
11. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21:195-218.
12. Carney JM. Oxidative stress leading to loss of critical proteases in Alzheimer's disease: an alternative view of the etiology of AD. Ann N Y Acad Sci. 2000;924:160-163.
13. Yuan J, Yankner BA. Apoptosis in the nervous system. Mature. 2000;407:802-809.
14. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron. 2002;35:9-12.
15. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985;36:2503-2508.
16. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 1995;4:257-269.
17. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598-605.
18. Hornykiewicz O, Pifl C, Kish SJ. Biochemical changes in idiopathic Parkinson's disease, aging, and MPTP parkinsonism: similarities and differences. In: Calne DB, Comi G, Crippa D, Horowski R, Trabucchi M, eds. Parkinsonism and Aging. New York, NY: Raven Press; 1989:57-68.
19. Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry. 2000;68:313-316.
20. Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl. 2000;59:133-154.
21. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994;36:765-770.
22. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992;32(suppl):S125-S127.
23. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
24. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
25. Venables WN, Ripley BD. Modern Applied Statistics With S-Plus. 3rd ed. New York: Springer-Verlag NY Inc; 1999.
26. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577-583.
27. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16:3507-3510.
28. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873-884.
29. 11C] dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-1299.
30. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 1994;117:501-507.
31. Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology. 1995;45:435-439.
32. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119:585-591.
33. Gibb WRG, Lees AJ. Pathological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, Boston: Butterworth-Heinemann; 1994:147-166.
34. Morrison BM, Hof PR, Morrison JH. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann Neurol. 1998;44:S32-S44.
35. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 1992;58:642-648.
36. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
37. Calne DB. Parkinson's disease is not one disease. Parkinsonism Relat Disord. 2000;7:3-7.
38. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-822.